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Abstract
Background: Studies on the association between prostate cancer and cadmium exposure have
yielded conflicting results. This study explored cadmium burden on the risk and phenotype of
prostate cancer in men with no evident environmental exposure.
Methods: Hospital-based 261 prostate cancer cases and 267 controls with benign diseases were
recruited from four hospitals in Taiwan. Demographic, dietary and lifestyle data were collected by
standardized questionnaires. Blood cadmium (BCd) and creatinine-adjusted urine cadmium
(CAUCd) levels were measured for each participant. Statistical analyses measured the prostate
cancer risk associated with BCd and CAUCd separately, controlling for age, smoking and
institution. BCd and CAUCd levels within cases were compared in relation to the disease stage and
the Gleason score.
Results: High family income, low beef intake, low dairy product consumption and positive family
history were independently associated with the prostate carcinogenesis. There was no difference
in BCd levels between cases and controls (median, 0.88 versus 0.87 μg/l, p = 0.45). Cases had lower
CAUCd levels than controls (median, 0.94 versus 1.40 μg/g creatinine, p = 0.001). However, cases
with higher BCd and CAUCd levels tended to be at more advanced stages and to have higher
Gleason scores. The prostate cancer cases with Gleason scores of ≥ 8 had an odds ratio of 2.89
(95% confidence interval 1.25-6.70), compared with patients with scores of 2-6.
Conclusion: Higher CAUCd and BCd levels may be associated with advanced cancer phenotypes,
but there was only a tenuous association between cadmium and prostate cancer.
Background
The incidence and mortality rates of prostate cancer vary
markedly among ethnic groups, being low in Asian and
much higher in Western populations. Nonetheless, the
incidence of the disease in Taiwan increased more than 3-
fold during the 1990s [1]. In addition to factors such as
age, race and inherited predisposition, dietary factors, par-
ticularly fat, may also play important roles in prostate car-
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cinogenesis [2,3]. Various other environmental and
occupational exposures have also been shown to be asso-
ciated with prostate cancer. These include cadmium expo-
sure, which has been investigated but with inconclusive
results. The association of cadmium exposure with pros-
tate cancer was reported by Potts in 1965 that three cad-
mium battery workers had died of the disease [4]. Several
subsequent occupational and geographical studies gave
conflicting results [5-11].
A geographical study in Spain showed that an area with
elevated cadmium contamination also had a high popula-
tion incidence of prostate cancer. However, the authors
did not conclude that cadmium was the determining
cause of prostate cancer; which probably has more to do
with nature occurrence of the chemical than with human
activity [9]. Occupational studies on cadmium exposure
may be not general population representative because
workers suffer much greater exposure than the general
population. Similarly, ecological studies have been una-
ble to address relevant confounding factors adequately. In
these occupational and ecologic studies, no cadmium was
measured in vivo to reflect the real human exposure and
this may have led to conflicting results. To determine
whether cadmium is an etiological or only a secondary
factor in prostate carcinogenesis, measurement of cad-
mium levels in vivo may be helpful. Feustel et al. [12]
measured the cadmium contents of prostate tissue and
found elevated levels in malignant tissues. Vinceti et al.
found that men in Italy with higher toenail cadmium are
at higher risk for prostate cancer [13]. No study has inves-
tigated the cadmium burden using blood cadmium (BCd)
and urine cadmium (UCd) levels among men with no
occupational exposure. This study determined and com-
pared the BCd and creatinine-adjusted urine cadmium
(CAUCd) levels among prostate cancer patients with dif-
ferent disease phenotypes and in controls.
Methods
Subjects
Cases, which were histologically confirmed prostate ade-
nocarcinoma, were recruited from four medical centers:
two hospitals from northern, one from central and one
from southern Taiwan. This recruitment plan was adopted
in an attempt to represent the likely span of cadmium
exposure across Taiwan as a whole. Controls were age-
matched male patients also from the same four hospitals
who had received medical attention from the services of
urology, family medicine, orthopedics, ophthalmology,
otolaryngology and other services. Subjects acquired from
the urology service were limited to those with inguinal
hernia or urolithiasis. Subjects with other malignancies,
hormonal disorders or benign prostatic diseases and men
with the prostate specific antigen >= 4 ng/ml were
excluded from the control group. This study was per-
formed with the approval of the ethics committee.
Data collection
With physician approval, all participants recruited gave
their informed consent prior to the study interview.
Trained interviewers conducted personal interviews with
all participants during hospital visits using standard ques-
tionnaires. The questionnaires covered information about
socio-demographic characteristics, occupation history,
tobacco and alcohol use, diet, physical activity, height and
weight history, medical history, and family history of
prostate cancer.
Using a food frequency questionnaire, both cases and
controls reported dietary intake history from 10 years ago,
determined by personal recall. The questionnaire was a
validated instrument and had been used in previous stud-
ies [14,15]. It had been modified during the past few years
to adapt it to the changing environment in our society.
The questionnaire contained the most frequently con-
sumed food items among Chinese, including poultry,
pork, beef, egg, fish, seafood, diary products, vegetables
and fruits, tofu, herbal preparations as food supplement,
and eating out including banquets. Food consumption
was reported at daily, weekly or monthly frequency. The
questionnaire also asked information about smoking and
some drink items including alcohol, coffee, soybean milk,
tea, etc. Since the dietary history was determined using the
semi-quantitative food frequency questionnaire, this ver-
sion was validated with a Cronbach's alpha ranging from
0.75 to 0.84.
Cancer stages and Gleason scores were extracted from
medical records. Among the 261 cases, these data were
available, respectively, for 220 (84.3%) and 210 (80.5%)
cases. Cancer stages were recoded in Taiwan by the Amer-
ican Urology Association (AUA) System, and Tumor,
Node and Metastasis (TNM) staging [1]. In this study, the
cancer stage recorded by TNM staging system was trans-
formed to the AUA system by a Urology specialist. Pathol-
ogists evaluated the architectural pattern of the glands of
prostate tumors on the basis of histological examinations
and gave scores representing the phenotype of prostate
cancer. The score ranges from 2 to 10, with 10 being asso-
ciated with the worst phenotype or prognosis.
Specimen collection and cadmium analysis
Since cadmium has a biological half-life of decades in
humans, blood and urine levels are considered fairly sta-
ble throughout the day. Therefore, single spot urine and
blood samples were collected during scheduled appoint-
ments instead of at a standardized time during the day.
The urine sample was collected in a sterile plastic cup and
an aliquot of 10 ml was transferred to a conical-bottomedBMC Cancer 2009, 9:429 http://www.biomedcentral.com/1471-2407/9/429
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cadmium-free plastic tube. Blood specimens of 2-3 ml
were collected in pre-screened heparin tubes, also from
lots verified to be free of cadmium contamination. Both
urine and blood specimens were stored at 4°C if analyzed
within a week or at -20°C if they were to be analyzed a
week or more later. One ml of urine was used for creati-
nine determination in order to normalize the urine cad-
mium levels.
One hundred μl of blood plus 900 μl of matrix modifier
(0.2% nitric acid, 0.5% Triton®-X-100 and 0.2%
(NH4)2HPO4) or 100 μl of urine plus 200 μl of matrix
modifier (25% NH4H2PO4 and 1.25% Mg(NO3)2) were
prepared for analyses [12]. Specimens, quality control
samples, and standards admixed with matrix modifier
were analyzed for cadmium contents using a Perkin-Elmer
Model 5100 PC atomic absorption spectrometer with Zee-
man background correction. For quality control, reference
blood samples (NYCOMED PHARMA AS, Oslo, Norway)
were used. Urinary cadmium analysis was verified every
other month using the Inter-Laboratory Comparison Pro-
gram, Le Centre de Toxicology du Québec (Sainte-Foy,
QC, Canada). The recovery rates for spike tests were 100.7
± 3.5% for urine analysis and 100.9 ± 3.6% for blood
analysis. The urine cadmium levels were adjusted for uri-
nary creatinine content.
Statistical analyses
Contingency tables with Chi-square tests were used to
examine the categorical variables to compare cases and
controls. The associations with major exposures and cov-
ariates were examined. We selected several variables from
three major categories - sociodemographics, lifestyle, and
food consumption - as the covariates. BCd and CAUCd
levels were examined by both parametric and non-para-
metric methods. Since neither level was normally distrib-
uted, medians BCd and CAUCd levels were compared
between cases and controls using the Wilcoxon rank-sum
test. Multivariate logistic regression models were used to
estimate the contribution of other factors such as socioe-
conomic status, dietary habit and family history. We also
compared the BCd and CAUCd levels by Kruskal-Wallis
test with post hoc comparisons (Dunn test) in cases
grouped according to tumor stages (A+B, C, and D) and
Gleason scores (2-6, 7, and >= 8) to check whether cad-
mium levels differed among graded malignant pheno-
types. The analyses that estimated the odds ratios for
association between cancer grade, by stage, and the
Gleason score, and median levels of CAUCd (<= 1.12 vs.
> 1.12 μg/g creatinine) and BCd (<= 0.87 vs. > 0.87 μg/L)
were based on available samples from cases. The signifi-
cance level was taken as p < 0.05 in this study.
Results
A total of 261 cases (age: 72.1 ± 6.8 years) and 267 con-
trols (age: 71.3 ± 7.2 years) were recruited. Comparisons
of sociodemographics, lifestyle and food consumption
showed no significant differences between cases and con-
trols in body mass index, education, occupation, smok-
ing, drinking or regular exercise. However, cases had a
significantly higher family income (p = 0.001). Subjects
with family histories of prostate cancer had a 3.4-fold
greater risk than those without such histories (p = 0.02).
Interestingly, cases tended to consume less beef (p = 0.04)
and dairy products (p = 0.046) but ate out more often (p
= 0.02) than controls (data not shown).
Among the participants, 234 (89.7%) cases and 248
(92.9%) controls provided urine samples and 176
(67.4%) cases and 147 (55.1%) controls donated blood
samples for cadmium measurements. Cases and controls
who provided urine specimens were similar in mean ages;
but among those who donated blood samples, the mean
age was 1.8 years greater in cases than in controls (data
not shown). Cases who provided either urine or blood
specimens were wealthier and ate out frequently. There
was no significant difference in education between cases
and controls.
Figure 1 shows that there was no significant difference
between cases and controls in median BCd levels (0.88
and 0.87 μg/l, respectively). The median CAUCd levels
were significantly lower in cases than in controls (0.94
and 1.40 μg/g creatinine, respectively, p = 0.001 by Wil-
coxon rank-sum test).
Table 1 shows that after adjusting for age, smoking and
the medical institution from which the subjects were
recruited, high family income, low beef intake and low
dairy product consumption remained significant inde-
pendent factors predicting an elevated risk of prostate can-
cer when BCd was included in the model. In addition to
these three factors, CAUCd and family history were also
independent factors associated with the risk of prostate
cancer when CAUCd was introduced into the model.
The distributions of tumor stages and Gleason scores were
comparable among all four hospitals. The median BCd
and CAUCd levels of cases with different tumor stages and
Gleason scores are shown in Table 2. Both BCd and
CAUCd levels tended to increase as tumor stage or
Gleason score progressed. By the non-parametric Kruskal-
Wallis test, significant differences in both BCd and
CAUCd levels were seen among patients with different
Gleason scores (p = 0.013 and 0.03, respectively). There
was a significant difference in CAUCd levels (but not BCd
levels) among patients at different stages (p = 0.043). Post
hoc comparison showed that patients with a Gleason
score of 7 had a higher BCd level than those with a score
of 6 or less (p = 0.004). Similarly, patients with a Gleason
score of 8 or more had a higher CAUCd level than those
with a score of 6 or less (p = 0.03). Patients with stage DBMC Cancer 2009, 9:429 http://www.biomedcentral.com/1471-2407/9/429
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disease had a higher CAUCd level than those with either
stage A+B (p = 0.04) or C (p = 0.04). The data were also
log-transformed and compared among stage groups and
among Gleason score groups using ANOVA. Similar sig-
nificance results were obtained.
Further data analyses showed that prostate cancer patients
diagnosed at the advanced stage had greater odds ratios
(OR) of having higher CAUCd and BCd, but this was not
significant (Figure 2). Compared with patients with the
Gleason scores of 2-6, the OR of prostate cancer being
associated with CAUCd levels higher than 1.12 μg Cd/g
creatinine increased to 1.24 (95% CI 0.64-2.42) for those
with a score of 7, and to 2.89 (95% CI 1.25-6.70) for those
with a score of 8 (p for trend 0.04). Higher Gleason scores
were also associated with higher BCd.
Discussion
Population aging, lifestyle changes and increased screen-
ing have resulted in a rapid increase in both the incidence
of and mortality from prostate cancer in low incidence
Asian countries. In our previous study [14,15] and the
present study, we investigated the association between
prostate cancer and socio-demographics, life style and die-
tary factors. In this study, we also investigated the associ-
ation between the cadmium burden and prostate cancer
risk, which has not previously been clearly delineated for
men based on the measured BCD and CAUCd.
Animal and occupational studies have strongly suggested
that cadmium is carcinogenic to the prostate [5,6,8,16-
19]. Waalkes et al. demonstrated a dose-response relation-
ship in a rodent model when tumors were induced by
injecting cadmium subcutaneously [19]. Animal experi-
ments are usually conducted at the maximum tolerated
doses or supra-normal levels of a certain toxin. Very few
studies have focused on general human populations
[13,20,21].
A small-scale Nigerian epidemiological study showed that
the plasma cadmium concentration is significantly higher
in subjects with prostate cancer than in normal subjects or
patients with benign prostatic hypertrophy [21]. There
were only 12 cancer patients in that study all with locally
advanced or metastatic disease. Vinceti et al. used toenail
cadmium as an indicator of body burden and found a sig-
nificant relationship between cadmium and prostate can-
cer; but, the statistical methods used were unstable, again
because of the small sample size [13]. Another study using
urinary cadmium as indicator showed a weak positive
relationship between cadmium and prostate-specific anti-
gen [20].
Occupational studies have also shown some evidences of
elevated risks upon substantial exposure [5,6,8]. BCd lev-
els normally range from 0.4 to 1.0 μg/l for nonsmokers
and from 1.4 to 4.0 μg/l for smokers [22]. In the event of
environmental or occupational exposure, BCd levels up to
10 μg/L may lead to renal dysfunction and/or osteopenia
[23]. CAUCd levels normally average 0.35 and > 2 μg/g
creatinine for nonsmokers and smokers, respectively [24].
For individuals with substantial occupational exposure,
BCd may rise up to 50 μg/L, and CAUCd up to 50 μg/g cre-
atinine [25]. This suggests that a very high body burden of
cadmium can occur in contaminated working environ-
ments, where the cadmium exposure is usually heavier
than that incurred by smoking. However, it may not be
appropriate to extrapolate data from rodent and occupa-
tional studies, in which high-dose exposures infer a rela-
tionship between cadmium burden and carcinogenesis in
the general human population. This may explain why
general observational studies, where no evident environ-
mental exposure is present, have failed to reveal consist-
ent results about the association of cadmium.
The present study demonstrated that men with prostate
cancer have lower CAUCd levels and there is no signifi-
cant difference in BCd level between cases and controls.
However, patients with higher Gleason scores were more
likely have higher cadmium burdens than patients with
lower scores.
The primary sources of cadmium exposure for the general
population are from smoking and contaminated food
[26]. BCd primarily reflects recent exposure rather than
whole body burden, while CAUCd is more indicative of
long-term body burden with some contribution from
recent exposure. Therefore, CAUCd seems a better marker
than BCd for assessing the association between cadmium
exposure and cancer risks [17,27]. Our data showed no
Comparisons of median blood and urine cadmium levels  between prostate cancer cases and controls Figure 1
Comparisons of median blood and urine cadmium 
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significant difference in BCd levels between cases and con-
trols. To our surprise, subjects with higher CAUCd had a
significantly lower risk for prostate cancer. This result con-
tradicted our previous belief that UCd might parallel BCd
in the association with the cancer risk. A possible explana-
tion is that cadmium is carcinogenic to the prostate; pros-
tate cancer may retain a significant amount of cadmium
(nor related to the circulation levels) [12,28] and allow
only trace amounts to be excreted via the kidney, in con-
trast to a benign prostate that does not "absorb" cadmium
and undergo malignant transformation. It may not matter
how much cadmium enters the body in total. What mat-
ters is how much the prostate "traps" the cadmium and
reacts to it. The change in CAUCd that we have observed
merely reflects a balance in cadmium content between
prostate tissue, blood and urine.
It may take decades for prostate epithelia to initiate and
promote during carcinogenesis. It also takes years for the
body cadmium burden to be eliminated after exposure.
Once absorbed, cadmium is transported through the
blood stream to various tissues. Cadmium in the liver and
kidney accounts about 50% of the total body burden [26],
as these organs synthesize large amounts of metal-
lothionein, a metal-binding protein with a high affinity
for cadmium. Cadmium is eliminated very slowly from
the body. Its biological half-life of cadmium has been esti-
mated as approximately 25-30 years in humans [29]. This
long biological half-life may well set the stage for neoplas-
tic transformation.
Our comparison of cadmium levels among cases with
graded malignancies revealed potentially interesting
results deserving careful interpretation and further study.
In patients with prostate cancer, there was a trend towards
higher tumor stages and worsening Gleason scores as the
BCd or CAUCd levels increased, except that the associa-
tion of BCd with tumor stages was not significant. Higher
Table 1: Multiple logistic regression analyses for factors associated with prostate cancer *
Variable Odds ratio
(95% CI)
p Variables Odds ratio
(95% CI)
p
Blood cadmium, μg/l Urine cadmium, μg Cd/g creatinine
≤ 0.87 1.0 0.24 ≤ 1.12 1.0 0.003
> 0.87 1.44 (0.78-2.64) > 1.12 0.49 (0.31-0.78)
Family income Family income
Median/low 1.0 0.002 Median/low 1.0 0.002
High 2.86 (1.45-5.61) High 2.25 (1.35-3.73)
Beef Beef
Less 1.0 0.041 Less 1.0 0.033
Frequent 0.53 (0.29-0.98) Frequent 0.60 (0.37-0.96)
Dairy products Dairy products
Less 1.0 0.065 Less 1.0 0.056
Frequent 0.49 (0.23-1.04) Frequent 0.58 (0.33-1.01)
Eating out Eating out
Less 1.0 0.309 Less 1.0 0.049
Frequent 1.39 (0.74-2.61) Frequent 1.62 (1.0-2.6)
Family history 0.095 Family history 0.045
No 1.0 No 1.0
Yes 4.41 (0.77-25.1) Yes 3.47 (1.03-11.7)
* Analysis was done by controlling for subjects' ages, smoking status and medical institutions; CI = confidence interval.
Table 2: Median and 5-95th percentile range of blood and urine cadmium levels in prostate cancer patients by stage and Gleason score
Stage N Median (5-95%) p* Gleason score N Median (5-95%) p*
Blood cadmium (μg/l)
A+B 56 0.85 (0.12-3.52) 0.285 2-6 88 0.74 (0.12-2.39) 0.013
C 34 0.89 (0.11-2.62) 7 41 1.03 (0.40-4.45)
D 73 0.92 (0.24-2.95) ≥ 8 22 0.91 (0.24-2.89)
Urine cadmium (μg Cd/g creatinine)
A+B 72 0.76 (0.10-3.95) 0.043 2-6 107 0.72 (0.12-3.72) 0.030
C 43 0.74 (0.14-2.91) 7 54 0.96 (0.13-4.37)
D 84 1.12 (0.21-4.37) ≥ 8 30 1.48 (0.17-7.36)
* By Kruskal-Wallis testBMC Cancer 2009, 9:429 http://www.biomedcentral.com/1471-2407/9/429
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cadmium levels appeared to be associated more with the
Gleason score than with tumor stage. CAUCd correlated
significantly more strongly than BCd with the malignant
phenotype of prostate cancer. The reason for this is
unclear. It has been shown that levels of cadmium in pros-
tate tissue are higher in more advanced diseases [12,28].
Patients with more advanced diseases may have first
entrapped more cadmium into the prostate during car-
cinogenesis and then excreted more cadmium into the
urine during disease progression and tumor necrosis than
those with more localized diseases or low-grade tumors.
However, as cadmium remains largely entrapped in the
cancerous prostate, the CAUCd levels in cases are still
lower than that in controls, especially in cases at earlier
stages and with lower grades.
Although we believe that low urinary cadmium levels are
associated with the entrapment of cadmium in the cancer-
ous prostate, it is also possible that some people who are
more sensitive to cadmium than others and thus may
therefore develop cancer even at low exposure levels.
The strength of this study includes the recruitment of
study subjects from medical centers distributed across all
areas in Taiwan, which may have reduced the bias from
patient selection, environmental exposure or dietary dif-
ferences. This study is one of the few that have actually
measured the cadmium burden in the general population
in order to study its association with the risk of prostate
cancer. Recall bias in terms of multiple items of risk expo-
sure was minimal. Since not all subjects donated speci-
mens for cadmium determination, it is possible that
differences in cadmium burden exist between specimen
donors and non-donors. However, this bias may also be
minimal because the smoking rates and socio-demo-
graphic parameters (such as education level) were similar
among donors and non-donors. The other strength is that
this is the first study to have associated cadmium exposure
with the stage and Gleason score of the disease. This inter-
esting relationship between prostate cancer phenotypes
and cadmium levels may be due to an effect of specific
tumor type and not to an etiological role of the metal.
Conclusion
This study provides new information regarding the non-
occupational cadmium exposure and the development of
prostate cancer. The cadmium level might be an indicator
of the progress of the disease, greater level in the more
advanced stage. Little evidence can be advanced to prove
that cadmium is a predictor of prostate cancer. Further
studies to clarify the pathways of cadmium metabolism in
the prostate and the genetic susceptibility that interacts
with cadmium may help in the understanding of cad-
mium-mediated prostate carcinogenesis.
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